(NASDAQ: ARQT) Arcutis Biotherapeutics's forecast annual revenue growth rate of 34.65% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 114.66%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.02%.
Arcutis Biotherapeutics's revenue in 2026 is $317,929,000.On average, 10 Wall Street analysts forecast ARQT's revenue for 2026 to be $58,388,353,161, with the lowest ARQT revenue forecast at $55,459,564,850, and the highest ARQT revenue forecast at $60,463,370,893. On average, 10 Wall Street analysts forecast ARQT's revenue for 2027 to be $76,377,556,478, with the lowest ARQT revenue forecast at $68,698,520,961, and the highest ARQT revenue forecast at $89,002,826,707.
In 2028, ARQT is forecast to generate $95,262,177,718 in revenue, with the lowest revenue forecast at $84,629,855,453 and the highest revenue forecast at $109,324,281,360.